- Home
- LNC vs ERAS Comparison
LNC vs ERAS Comparison
Compare LNC & ERAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | LNC | ERAS |
|---|---|---|
| Founded | 1905 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Life Insurance | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.0B | 6.3B |
| IPO Year | 1994 | 2021 |
Fundamental Metrics
Financial Performance| Metric | LNC | ERAS |
|---|---|---|
| Price | $40.90 | $14.27 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 13 | 9 |
| Target Price | ★ $47.83 | $24.11 |
| AVG Volume (30 Days) | 1.8M | ★ 4.9M |
| Earning Date | 11-05-2026 | 11-11-2026 |
| Dividend Yield | ★ 4.35% | N/A |
| EPS Growth | N/A | ★ 36.23 |
| EPS | ★ 5.65 | N/A |
| Revenue | ★ $18,212,000,000.00 | N/A |
| Revenue This Year | $8.34 | N/A |
| Revenue Next Year | $3.80 | N/A |
| P/E Ratio | $7.32 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $32.18 | $2.11 |
| 52 Week High | $47.67 | $24.28 |
Technical Indicators
Market Signals| Indicator | LNC | ERAS |
|---|---|---|
| Relative Strength Index (RSI) | 50.71 | 44.01 |
| Support Level | $38.83 | $13.47 |
| Resistance Level | $42.68 | $15.03 |
| Average True Range (ATR) | 0.93 | 0.96 |
| MACD | 0.21 | 0.09 |
| Stochastic Oscillator | 69.93 | 43.75 |
Price Performance
Historical ComparisonAbout LNC Lincoln National Corporation
Lincoln National Corp operates multiple insurance and retirement businesses. The company's operating segment includes Annuities; Retirement Plan Services; Life Insurance and Group Protection. Its products include fixed and indexed annuities, variable annuities, universal life insurance (UL), variable universal life insurance (VUL), linked-benefit UL and VUL, indexed universal life insurance (IUL), term life insurance, employer-sponsored retirement plans and services, and group life, disability, and dental.
About ERAS Erasca Inc.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Its focused RAS/MAPK pathway pipeline comprises modality-agnostic programs aligned with three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Its pipeline includes two clinical-stage programs (ERAS-0015, a pan-RAS molecular glue; and ERAS-4001, a pan-KRAS inhibitor), and ERAS-12, a discovery-stage program.